Published in Genetics and Environmental Health Week, January 17th, 2007
Trastuzumab-MCC-DM1 is being developed by Genentech and uses ImmunoGen's Tumor-Activated Prodrug (TAP) technology.
The compound comprises Genentech's trastuzumab anti-HER2 antibody and ImmunoGen's DM1 cell-killing agent. ImmunoGen's TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells.
"We're delighted with the clinical findings with trastuzumab-MCC-DM1 being...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.